INSIGHTS ON CELL & GENE OUTSOURCING ISSUES
-
![investors-biotech-GettyImages-1498705688]( "The Rise Of Chinese Biotechs And The Global CRO Question")
The Rise Of Chinese Biotechs And The Global CRO QuestionAs innovative therapies move beyond home markets, early planning across regulators and geographies helps avoid costly delays and protect trial budgets.
-
![IDT Biologika Filling Line (1)]( "Fill-Finish Solutions That Grow With Your Program")
Fill-Finish Solutions That Grow With Your ProgramMoving from clinical to commercial manufacturing? Learn how flexible fill-finish solutions, scalable capacity, and integrated support can help drive efficiency and readiness.
-
![OPCUAug26MilliporeRev]( "From Lipids To Launch: End-To-End Therapy Development")
From Lipids To Launch: End-To-End Therapy DevelopmentExplore integrated capabilities spanning lipid manufacturing, nanoparticle formulation, and more with support designed to move complex therapies from preclinical development through commercialization.
-
![AKTA Process Chromatography System]( "Maintain Performance And Reduce Downtime")
Maintain Performance And Reduce DowntimeSee how modernizing aging chromatography system controls can reduce downtime risk, improve serviceability, and support validated workflows through updated hardware and operating systems.
-
![Service Care Packages]( "New Promises, New Pressures, No Problem - Service Care Packages")
New Promises, New Pressures, No Problem - Service Care PackagesTighter production schedules leave little room for equipment disruption. Get support that can strengthen maintenance strategies, reduce operational risk, and help internal teams sustain performance.
-
![S18_Merck_2026_MLAB-6 (1)]( "Bioprocessing Ecosystem For Downstream And Mixing")
Bioprocessing Ecosystem For Downstream And MixingModernize your drug manufacturing by exploring an integrated approach designed to support facility expansion, simplify implementation, and help production operations adapt as demand evolves.
-
![uniqueness, expertise, differently abled, inclusiveness, diversity-GettyImages-2261212848]( "What Goes Into Restarting A Shelved Orphan Drug Candidate?")
What Goes Into Restarting A Shelved Orphan Drug Candidate?The Orphan Therapeutics Accelerator wants to help viable clinical-phase products reach patients. Its cofounder describes the complexity of rebooting a shelved candidate.
-
![Lonza Cell Dev Aug 2026 OPCU]( "Lonza Capabilities Update August 2026: Cell Line Development")
Lonza Capabilities Update August 2026: Cell Line DevelopmentOmeco Barrett, Principal Scientist, Global Process Development, highlights Lonza’s latest development in cell line expression technology and cell line development (CLD).
-
![GettyImages-1404912204-lab-sample-analyze-blood-test-tube]( "Beyond Sensitivity: Building A Robust Multi-Matrix AAV Shedding Assays")
Beyond Sensitivity: Building A Robust Multi-Matrix AAV Shedding AssaysAAV gene therapy shedding studies demand matrix-specific extraction, not a one-size-fits-all approach. See how validated multi-matrix assays achieve 99-100% accuracy across blood, saliva, semen, serum, and urine.
-
![GettyImages-1295693748-mRNA-strand]( "mRNA Development And Manufacturing Services")
mRNA Development And Manufacturing ServicesOur end-to-end mRNA CDMO platform covers synthesis, LNP formulation, fill-finish, and QC under one roof — from early clinical to commercial scale-up to 100g.
